奥曲肽与微量泵持续皮下胰岛素泵入联合治疗糖尿病酮症酸中毒的临床疗效与作用机制分析  

Clinical Efficacy and Mechanism Analysis of Octreotide Combined with Micropump Continuous Subcutaneous Insulin Infusion in the Treatment of Diabetic Ketoacidosis

作　　者：唐梅萍 吕美煌 杜文超 TANG Meiping;LYU Meihuang;DU Wenchao(Department of Emergency,Longyan First Hospital,Longyan 364000,Fujian,China)

机构地区：[1]龙岩市第一医院急诊科,福建龙岩364000

出　　处：《糖尿病新世界》2025年第5期186-188,194,共4页Diabetes New World

摘　　要：目的分析奥曲肽联合微量泵持续皮下胰岛素泵入技术(continuous subcutaneous insulin infusion,CSII)在糖尿病酮症酸中毒(diabetic ketoacidosis,DKA)治疗中的临床效果及其作用机理。方法选取2022年1月—2023年12月在龙岩市第一医院就诊的102例DKA患者,根据不同治疗方法分为两组,每组51例。对照组接受静脉滴注胰岛素联合奥曲肽治疗,观察组则接受CSII联合奥曲肽治疗。对比两组血糖水平、血气水平、不良反应发生情况。结果治疗后,相比对照组,观察组血糖、糖化血红蛋白水平、不良反应发生率均更低,pH值、HCO3-、二氧化碳结合力水平均更高,差异均有统计学意义(P均<0.05)。结论奥曲肽与CSII联合治疗DKA较传统静脉滴注胰岛素联合奥曲肽治疗,能够更有效地降低血糖水平,改善血气指标,并减少并发症的发生。Objective To analyze the clinical effect and mechanism of octreotide combined with continuous subcutaneous insulin infusion(CSII)in the treatment of diabetic ketoacidosis(DKA).Methods A total of 102 patients with DKA who were treated in Longyan First Hospital from January 2022 to December 2023 were selected and divided into two groups according to different treatment methods,with 51 cases in each group.The control group was treated with intravenous infusion of insulin combined with octreotide,while the observation group was treated with CSII combined with octreotide.The blood glucose levels,blood gas levels and adverse reaction were compared between the two groups.Results After treatment,compared with the control group,the levels of plasma glucose,glycated hemoglobin A1c and the incidence of adverse reaction in the observation group were lower,the levels of pH,HCO3-and carbon dioxide binding capacity were higher,and the differences were statistically significant(all P<0.05).Conclusion The combined treatment of octreotide and CSII can reduce blood glucose level,improve blood gas index and reduce the incidence of complications compared with the traditional intravenous infusion of insulin and octreotide.

关 键 词：糖尿病酮症酸中毒 奥曲肽 持续皮下胰岛素泵入 血糖水平 不良反应 

分 类 号：R587[医药卫生—内分泌]